A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

Phase 4

Completed

• Conditions: Gaucher Disease
• Interventions: Other: Digital Engagement Application (GD App); Other: No Intervention

• Registration Number: NCT04718779
• Lead Sponsor: Takeda

Brief Summary

The study will provide information on outcomes in people with type 1 Gaucher disease when they are treated with velaglucarase alfa (also called VPRIV), under standard care. Standard care means the participant will be treated according to the clinic's standard practice. The study sponsor will not be involved in how participants are treated with VPRIV, will provide instructions on how the clinic will record what happens during the study.

VPRIV is a type of enzyme replacement therapy (also known as ERT). Before starting the study, participants must either have switched from substrate reduction therapies (SRT) to VPRIV or switched from other enzyme replacement therapies to SRT then finally to VPRIV. During this time, medical data will be collected from the participants' medical records.

During the study, participants will be treated with VPRIV according to their clinic's standard practice. VPRIV is given by a slow injection into the vein, also known as an infusion. This will happen in the clinic or at home.

The study will record if blood levels of specific substances remain stable or improve during the switch to treatment with VPRIV. Some of these substances will show if organs such as the liver or spleen are working well. Others are blood cells that help blood to clot, known as platelets. Another is a substance in a red blood cell used to carry oxygen around the body, known as hemoglobin.

Participants will use a digital tool so they can be more involved in decision making in their treatment. The digital tool is a mobile phone app, in which each participant can log their daily activities, their general health and wellbeing, and other key information.

Medical data will also be collected from the participants' charts during this time.

Health problems of the participants will be recorded during the study to check if there were any side effects from VPRIV treatment.

Participants will be in this study for up to 12 months.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-01-20
• Study First Submitted QC: 2021-01-20
• Study First Posted: 2021-01-22
• Study Start: 2021-04-22
• Primary Completion: 2023-02-16
• Study Completion: 2023-02-16
• Results First Submitted: 2023-11-15
• Status Verified: 2023-12
• Results First Submitted QC: 2023-12-20
• Last Update Submitted: 2023-12-20
• Results First Posted: 2023-12-21
• Last Update Posted: 2023-12-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

Participant eligibility is determined according to the following criteria prior to entry into the study:

• In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
• Participant either signs and dates a written, informed consent form or completes an e-consent process prior to the initiation of any study procedures.
• Participant has been diagnosed with GD type I; diagnosis was confirmed biochemically and/or genetically.
• Participant has been treated with SRT for at least 3 months prior to switch to VPRIV.
• Participant has been treated with VPRIV at least 3 months prior to enrollment (Baseline [Day 0]).
• Participant is aged 18 or older.
• Arm A: Participant is able to use mobile application based on clinician's judgment, (e.g., owns an iPhone version 5 or later or smartphones with Android operating systems, have an active data plan or regular Wi-Fi access).
• Arm A: The participant's primary language is English.

Read More

Exclusion Criteria

Any participant who meets any of the following criteria will not qualify for entry into the study:

• Participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
• Participant is judged by the investigator as being ineligible for any other reason.
• Participant has L444P/L444P GBA1 genotype (c.1448T greater than [>] C).
• Participant has Parkinson's disease, a history of central nervous system [CNS] manifestations, or any other neurological disorder (e.g. Lewy Body Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple sclerosis).

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm A: Prospective	Digital Engagement Application (GD App)	Participants with Gaucher's Disease 1 (GD1) transitioning from SRTs to ERT (VPRIV) or ERT to SRT and then to ERT (VPRIV) in a real-world setting among adults 18 and older will be studied by observing standard patient care and by reviewing the results of tests and assessments that would be performed as part of their routine treatment.
Arm B: Retrospective	No Intervention	Participants with GD1 transitioning from SRT to ERT (VPRIV) or ERT to SRT and then to ERT (VPRIV) previously (within the past 5 years at the time of enrollment) will be assessed retrospectively after switch to ERT for up to 12 months.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Clinically Stable Hemoglobin (Hb) Concentration From Baseline up to Month 12	From Baseline up to Month 12	Hemoglobin concentration level was assessed from the blood sample. Clinical stability from baseline was calculated using prespecified threshold of hemoglobin concentration level less than (\<) 1.5 gram per deciliter (g/dl) decrease level. Number of participants with clinically stable hemoglobin from baseline up to Month 12 were reported.
Number of Participants With Clinically Stable Platelet Count From Baseline in Platelet Count up to Month 12	From Baseline up to Month 12	Platelet count concentration level was assessed from the blood sample. Clinical stability from baseline was calculated using prespecified threshold of platelet count \< 25 percent (%) decrease levels. Number of participants with clinically stable platelet count from baseline up to Month 12 were reported.
Number of Participants With Clinically Stable Liver Volume From Baseline up to Month 12	From Baseline up to Month 12	Clinical stability from baseline was calculated using prespecified threshold of liver volume \< 20 % increase, was assessed using ultrasound or Magnetic Resonance Image (MRI). Number of participants with clinically stable liver volume from baseline up to Month 12 were reported.
Number of Participants With Clinically Stable Spleen Volume From Baseline up to Month 12	From Baseline up to Month 12	Clinical stability from baseline was calculated using prespecified threshold of spleen volume \< 25 % increase was assessed using ultrasound or MRI. Number of participants with clinically stable spleen volume from baseline up to Month 12 were reported.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	From start of the study up to Month 12	An AE was defined as any untoward medical occurrence in a clinical investigation participant administered with a drug; it does not necessarily have to have a causal relationship with the treatment. An SAE was any event that resulted in: death; was life-threatening; required inpatient hospitalization or resulted in prolongation of existing hospitalization; persistent or significant disability/incapacity; was a congenital anomaly/birth defect or a medically important event. AEs included both SAEs, and non-serious AEs.

Trial Locations

Locations (1)

The Lysosomal and Rare Disorders Research and Treatment Center; 🇺🇸 Fairfax, Virginia, United States